FF Founder Flair

Leen Kawas on Championing Women Scientist-Entrepreneurs

Kian Carroll

In the world of life sciences, the path from laboratory to market is demanding. It requires technical excellence, business acumen, and an ability to navigate high-stakes decision-making under constant scrutiny. For women scientist-entrepreneurs, the path can be even steeper. Leen Kawas—co-founder and managing general partner of Propel Bio Partners—knows this firsthand.

Kawas’s own career, from academic research to leading Athira Pharma’s $400 million IPO, gives her a rare vantage point. She has seen the hurdles women face at every stage of the innovation pipeline and has made championing their success a priority in her work as an investor and mentor.

Seeing the Gaps in the System

As a scientist-turned-CEO, Leen Kawas learned early that merit alone is not always enough to secure opportunities. Women in biotech often face fewer networking connections, less access to capital, and persistent bias about their technical and leadership capabilities. These gaps are not just personal setbacks—they slow the pace of innovation by leaving talent underutilized.

Kawas’s time raising capital for Athira made the disparities vivid. Investor rooms were often male-dominated, and the stories of women leading breakthrough science were less frequently told. She recognised that without intentional change, many women-led ventures would struggle to get the visibility and resources they deserved.

Investing With Intent

At Propel Bio Partners, Kawas uses her platform to shift that dynamic. The fund supports life science companies with strong science and scalable potential, and Kawas is deliberate about identifying women-led ventures within that scope. She believes the combination of scientific expertise and entrepreneurial drive that women bring is a competitive advantage—not an exception to be explained.

Her approach is to meet founders where they are. That might mean providing seed-stage capital to help move a discovery toward proof-of-concept, or joining later rounds to fuel clinical trials and market entry. Just as importantly, she offers operational guidance drawn from her own experience navigating regulatory approvals, managing investor expectations, and scaling a biotech company from inception to public offering.

Mentorship Beyond Capital

Kawas is clear that funding alone does not solve the systemic challenges women scientist-entrepreneurs face. She invests time in mentorship, helping founders refine their business narratives, strengthen their leadership presence, and position themselves strategically within their industries.

She encourages women to own their expertise rather than frame themselves as “exceptions” in the field. In her view, the most effective leaders are those who balance confidence in their scientific vision with openness to the business realities of bringing a product to market.

Changing the Conversation in Boardrooms

One of Kawas’s goals is to normalise the presence of women scientists in decision-making roles—whether as founders, CEOs, or board members. She notes that women in leadership often bring diverse perspectives on risk assessment, team culture, and stakeholder engagement, all of which are vital in a sector where missteps can be costly. Her interview on Principal Post goes into further detail.

Her own career offers proof of concept. At Athira, she guided the company through complex scientific, regulatory, and financial milestones, demonstrating that technical expertise and executive leadership are not mutually exclusive. That experience allows her to speak with authority when advocating for more inclusive investment practices.

Building Networks That Last

Kawas also focuses on building networks where women can exchange knowledge and opportunities. She supports forums and initiatives that connect women scientists, entrepreneurs, and investors, recognising that peer support can accelerate both individual careers and collective influence.

These networks help counter the isolation that can come with being one of the few women in a leadership role. They also create visibility for role models, showing early-career scientists what is possible when technical skill is matched with entrepreneurial ambition.

The Broader Impact on Innovation

For Kawas, championing women scientist-entrepreneurs is not just a matter of equity—it is a way to strengthen the life sciences sector as a whole. More diverse leadership teams tend to pursue a wider range of research questions, address overlooked markets, and design solutions with broader applicability.

In a field where the stakes include patient health and quality of life, leaving potential untapped is not just inefficient—it is costly. By helping women-led companies access capital and strategic support, Leen Kawas aims to ensure that promising innovations reach the patients who need them.

Looking Forward

Kawas remains optimistic about the trajectory of women in science and entrepreneurship. She sees growing recognition in the investment community that diversity is linked to stronger performance and better problem-solving. But she is also realistic: the pace of change will depend on continued effort from both investors and industry leaders.

Her role, as she sees it, is to keep building pathways—through capital, mentorship, and advocacy—so that more women scientists can step into entrepreneurial leadership without having to fight the same battles she did.

In doing so, Kawas is not only amplifying individual careers but also shaping the culture of life sciences toward one where talent, not gender, defines opportunity. For her, that shift is essential to unlocking the next wave of breakthroughs that will define the future of healthcare.

To learn more about what Leen Kawas is currently up to, check out Eit Pharma.